{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:36:37Z","timestamp":1762875397916,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.03.010","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:35:15Z","timestamp":1311564915000},"page":"189-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Is There a Role for \u201cWatch and Wait\u201d in Patients With Mantle Cell Lymphoma?"],"prefix":"10.1053","volume":"48","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.03.010_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/annonc\/mdn045","article-title":"Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies","volume":"19","author":"Martin","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib4","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma following intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a non-randomized phase-II multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib5","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib6","first-page":"110","volume":"116","author":"Hermine","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jcp.2005.030783","article-title":"\u201cIn situ-like\u201d mantle cell lymphoma: a report of two cases","volume":"59","author":"Richard","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2559.2007.02906.x","article-title":"In-situ mantle cell lymphoma\u2014a report of two cases","volume":"52","author":"Aqel","year":"2008","journal-title":"Histopathology"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib9","first-page":"323","article-title":"Evidence of long latency periods prior to development of mantle cell lymphoma","volume":"116","author":"Racke","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00428-008-0621-x","article-title":"Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?","volume":"453","author":"Bassarova","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib11","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib12","first-page":"9575","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"35","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib14","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","article-title":"Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes","volume":"34","author":"Nodit","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib17","first-page":"1780","article-title":"Indolent mantle cell lymphoma (MCL): a retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profiling analysis","volume":"112","author":"Thieblemont","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"18 suppl","key":"10.1053\/j.seminhematol.2011.03.010_bib18","first-page":"8039","article-title":"Survival of CD23-positive (CD23+) mantle cell lymphoma (MCL) compared to classic CD23-negative (CD23-) MCL: biologic correlates and clinical outcomes in a 10-year analysis","volume":"25","author":"Evens","year":"2007","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib20","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib21","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3324\/haematol.2009.010173","article-title":"Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR","volume":"94","author":"Quintanilla-Martinez","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib23","first-page":"138","article-title":"Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in an independent prospective patient cohort","volume":"114","author":"Hoster","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib24","first-page":"2682","article-title":"CHOP-R + bortezomib as initial therapy for mantle cell lymphoma (MCL)","volume":"114","author":"Ruan","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib25","first-page":"2703","article-title":"Validation of the Mantle Cell Lymphoma Prognostic Index (MIPI): a valuable tool for risk stratification in mantle cell lymphoma","volume":"114","author":"Smith","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib26","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma\u2014consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib30","first-page":"264","article-title":"Cdk4\/6 Inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle cell lymphoma","volume":"112","author":"Leonard","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic hypermutation and VH gene usage in mantle cell lymphoma","volume":"68","author":"Thors\u00e9lius","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib32","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/modpathol.3800677","article-title":"Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome","volume":"19","author":"Lai","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2008.199","article-title":"Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity","volume":"22","author":"Schraders","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib34","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib35","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib37","first-page":"3093","article-title":"FDG-PET as a marker of tumor proliferation compared to gene-expression proliferation scores, MIB1%, and LDH in untreated mantle cell lymphoma (MCL)","volume":"116","author":"Roschewski","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.03.010_bib38","first-page":"147P-c","article-title":"Comparison of FDG- and FLT-PET\/CT in a multi-center phase Ib trial of a novel anti-proliferative cyclin dependent kinase (cdk) inhibitor in treatment of recurrent mantle cell lymphoma","volume":"49","author":"Yap","year":"2008","journal-title":"J Nucl Med Meeting Abstracts"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:54Z","timestamp":1758522054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000370"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Role for \u201cWatch and Wait\u201d in Patients With Mantle Cell Lymphoma?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}